Research
Embedded Files
The Brigant Laboratory is dedicated to advancing the understanding of connective tissue disorders and exploring chondrocyte biology under pathological conditions, focusing on genetic disorders (Ehlers-Danlos syndrome, MULIBREY nanism) and osteoarthritis.
By leveraging cutting-edge technologies such as genome editing, functional genomics, and phenotypic models, our goal is to identify new disease mechanisms associated with inflammation, cartilage degradation, and rare gene mutations.
We aim to develop translational studies to validate our fundamental discoveries in patients to identify new therapeutic targets and biomarkers to improve the diagnosis and treatment of patient with rare diseases.
Additionally, the Brigant Laboratory seeks to push the boundaries of research. We actively pursue projects that lay the foundation for new discoveries and innovations, ultimately leading to solutions for societal health challenges.
Below, you can find our five core research themes.
Ehlers-Danlos syndromes (EDS) are a group of rare inherited conditions that affect connective tissue. Connective tissues provide support in skin, tendons, ligaments, blood vessels, internal organs and bones.
Discovery of new potential target in chondrocytes to prevent cartilage loss.
Development of CRISPR therapies
TRIM37 is also known as the MULIBREY protein, and MULIBREY nanism (muscle–liver–brain–eye) is a rare autosomal recessive disorder that affects several tissues of mesodermal origin, presenting with severe pre- and postnatal growth failure, characteristic dysmorphic features, but normal neurological development.
Inflammation
Inflammation
Inflammation plays a significant role in joint disease and contributes to the progression of joint degeneration.
CRISPR
CRISPR
CRISPR technologies hold immense promise for developing innovative treatments for joint diseases, particularly Ehlers-Danlos syndrome.
Page updated
Google Sites
Report abuse